Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2612)	1/19/2001 6:40:58 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 52153

AMGN decision with link to 245 pg opinion. I think I will skip it. <g> ij Friday January 19, 5:30 pm Eastern Time FACTBOX-Summary of Amgen-Transkaryotic decision BOSTON, Jan 19 (Reuters) - The following is a summary of a U.S. district court decision in the patent case pitting biotechnology firms Amgen (NasdaqNM:AMGN - news) and Transkaryotic Therapies Inc (NasdaqNM:TKTX - news) over Amgen's blockbuster anti-anemia drug Epogen: Claims 1, 2, and 9 of the '933 patent are not infringed, and if this finding is error, those claims are invalid for lack of an adequate written description, indefiniteness, and lack of entablement . Claims 4 though 9 of the '698 patent are not infringed. Claims 2 through 4 of the '080 are valid, enforceable, and infringed under the doctrine of equivalents. Claims 1, 3, 4, and 6 of the '349 patent are valid, enforceable, and literally infringed, whereas Claim 7 of the same patent is not infringed. *Claim 1 of the '422 patent is valid, enforceable, and literally infringed. A full copy of the entire decision is available on the web at mad.uscourts.gov.